The Board of Directors of Milestone Medical Inc. (WAR: MMD, “the Company”, “the Issuer”), today announced that the abstract previously submitted to the prestigious Journal of Pain has been accepted for presentation and publication. The abstract, entitled, “Real-Time Epidural Space Identification with the Compuflo® Epidural Instrument is Equivalent to Loss of Resistance Technique Coupled with the Fluoroscopy Confirmation,” will detail the results of the Company’s prospective, open labeled, clinical trial assessing the CompuFlo® technology in correctly identifying the epidural space during an epidural procedure.
The abstract has been accepted for presentation as a poster at the 35th Annual Scientific Meeting of the American Pain Society, May 11-14, 2016 at the Austin Convention Center, Austin, TX. The abstract will be published in a supplemental issue of the Journal of Pain. The Journal of Pain will also publish the abstract in an online searchable database about 6 weeks prior to the annual meeting.
Milestone Medical designed the study, in conjunction with its Scientific Advisory Board, and in agreement with the U.S. Food and Drug Administration (FDA), to assess the safety and effectiveness of the pressure sensing technology in identification of the epidural space.
The Board of Directors of the Issuer is pleased to announce that its abstract detailing the results of this clinical trial has been accepted for publication in the prestigious Journal of Pain. The Board of Directors of the Company looks forward to formally presenting the data at the 35th Annual Scientific Meeting of the American Pain Society this spring.
Legal basis: § 3 subparagraph 1 of the Exhibit 3 to the Alternative Trading System Rules “Current and Periodical Information in the Alternative Trading System on the NewConnect Market".
Osoby reprezentujące spółkę:
Joseph D'Agostino - Chief Financial Officer